

1 ORIGINAL RESEARCH

2 Zen et al

3 **A Multi-center Study of COVID-19 with Multivariate Prognostic**

4 **Analysis**

5

6 Wen Zeng*¹

7 Xin Feng*¹,

8 Jie Huang*²

9 Chuan Du*³

10 Dongming Qu*⁴

11 Xiang Zhang⁵

12 Jianquan Zhang¹

13 ¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical
14 University, Nanning, Guangxi 530021, China

15 ²The Fourth People's Hospital of Nanning City, Nanning, Guangxi, 530021, China

16 ³Hubei No.3 People's Hospital of Jiangnan University, Wuhan, Hubei,430000, China

17 ⁴Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, 541000, China

18 ⁵Wuhan Huangpi District Hospital of Traditional Chinese Medicine, Wuhan, Hubei, 430000, China

19 * These authors contributed equally to this project and should be considered co-first authors.

20 **Correspondence:**

21 Jianquan Zhang, MD, PhD

22 Department of Respiratory and Critical Care Medicine,1 Guangxi 530021, China

23 E-mail: jqzhang2002@126.com

24 Tel.: +86 139 7812 3845

25 Fax: +86 0771 535 0031

26

27 **Abstract:**

28 **Purpose:** Coronavirus disease (COVID-19) pandemic is now a global health concern.

29 However, there is no detailed analysis of the factors related to patients' improvement.

30 **Patients and methods:** We compared the clinical characteristics, laboratory findings, CT
31 images, and treatment of COVID-19 patients from two different cities in China. One hundred
32 and sixty-nine patients were recruited from January 27 to March 17, 2020 at five hospitals in
33 Hubei and Guangxi. They were divided into four groups according to age and into two groups
34 according to presence of comorbidities. Multivariate statistical analyses were performed for
35 the prognosis of the disease.

36 **Results:** Fifty-two patients (30.8%) had comorbidities, and the percentage of critical
37 COVID-19 was higher in the comorbidities group (11.6% vs. 0.9%, $p < 0.05$). Older patients had
38 higher proportion of severe or critical disease. The results showed that lymphocyte count was
39 significantly associated with the number of days from positive COVID-19 nucleic acid test to
40 negative test; number of days from onset of symptoms to confirmation of diagnosis was
41 significantly associated with the time it took for symptoms to improve; and number of days
42 from onset of symptoms to confirmation of diagnosis and disease severity were significantly
43 associated with chest computed tomography improvement.

44 **Conclusions:** Age, comorbidities, lymphocyte count, and SpO₂ may predict the risk of severity
45 of COVID-19. Early isolation, early diagnosis, and early initiation of management can slow
46 down the progression and spread of COVID-19.

47

48 **Keywords:** COVID-19; Severity; Multiple lung lobe involvement, prognosis

49 **Key Points:** Age and comorbidities can predict the risk of severity of COVID-19,
50 Lymphocyte count and SpO₂ may predict the risk of severity of COVID-19. Early isolation,
51 Early diagnosis can slow down the progression of COVID-19

52

53 **1.Introduction**

54 Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome
55 coronavirus2 (SARS-CoV-2), has spread throughout the world, posing a critical threat to
56 global health. COVID-19 has been declared as a public health emergency by the World Health
57 Organization, and 3,175,207 laboratory-confirmed infections had been reported globally by
58 May 1, 2020.¹ Several studies have described the clinical characteristics and epidemiology of
59 COVID-19.²⁻⁶ The novel corona virus has caused clusters of severe respiratory illness, similar
60 to severe acute respiratory syndrome coronavirus.^{2,5} Previous studies have also summarized
61 the early clinical, laboratory, and computed tomography (CT) findings of COVID-19
62 pneumonia.^{3,6} A multi-center study of clinical features showed that multiple organ dysfunction
63 and impaired immune function were the typical characteristics of severe and critical disease,
64 and advanced age (≥ 75 years) was a risk factor for mortality.⁴ However, there is no detailed
65 analysis of the factors related to patients' improvement. In this study, we analyzed the clinical
66 features, laboratory findings, CT images, outcomes, and therapies (including antiviral drugs,
67 antibacterial drugs, and corticosteroids) in 169 COVID-19 cases from three cities (Nanning and
68 Guilin in Guangxi Province, and Wuhan in Hubei Province). We also analyzed the factors
69 related to patients' improvement.

70

71 **2.Methods**

72 2.1. Study design and participants

73 Patients who were ≥ 18 years old were recruited for this multi-center retrospective study from
74 five hospitals designated for the treatment of COVID-19 in China, namely Guangxi Medical
75 University First Affiliated Hospital and The Fourth People's Hospital of Nanning City, both in
76 Nanning; Nanxishan Hospital of Guangxi Zhuang Autonomous Region, in Guilin, Guangxi
77 Province; and Wuhan Huangpi District Hospital of Traditional Chinese Medicine and Hubei
78 No.3 People's Hospital of Jiangnan University, both in Wuhan, Hubei Province. The
79 recruitment period was from January 27 to March 17, 2020. All patients enrolled in this study
80 were diagnosed with COVID-19 according to the diagnostic criteria from the Chinese Clinical
81 Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition), which was
82 produced by the National Health Commission of China.⁷ The study was approved by the
83 Research Ethics Commission of Guangxi Medical University First Affiliated Hospital
84 approval number: 2020(KY-E-06).

85 We grouped the patients according to their ages into group A (18–44 years), group B (45–64
86 years), group C (64–74 years), and group D (>75 years). Analysis of prognosis of improvement
87 included three aspects: number of days from positive COVID-19 nucleic acid test to negative
88 test, number of days from onset of illness (the first day of presenting with COVID-19-related
89 symptoms, such as fever, cough, and diarrhea) to improvement in symptoms, and improvement
90 on the second CT scan. The primary outcomes were improvement and death.

91

92 2.2. Definitions

93 According to the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and
94 Treatment (7th edition), COVID-19 is classified by severity into mild, moderate, severe, and
95 critical types.⁷

96

97 2.3. Data collection

98 The medical records of the recruited COVID-19 patients were reviewed and general
99 information, epidemiological data, and data on clinical presentation, laboratory tests, chest CT
100 scan findings, treatment modalities, and outcome were collected. Clinical data collection was
101 completed on March 17, 2020. Du Chuang and Huang Jie cross-checked the data. The local
102 Center for Disease Control (CDC) laboratories made definitive diagnosis of COVID-19 by
103 analyzing throat-swab specimens from the upper respiratory tract or feces. Real-time reverse
104 transcription polymerase chain reaction (RT-PCR) was used to confirm COVID-19² and
105 exclude other viral infections. All patients underwent chest CT scan. Two attending
106 radiologists were invited to interpret all chest CT scans independently, and they were blinded
107 to the clinical information of each patient. The following CT features were assessed:
108 distribution of lesions (peripheral, along the bronchi, random, or diffuse), number of lobes
109 involved (one, two or three, or four or five), shape of lesions (patchy or nodular), appearance
110 (ground-glass opacity [GGO], consolidation, or GGO with consolidation), specific focal signs
111 (vascular thickening, crazy paving pattern, and fibrosis), and extrapulmonary manifestations
112 (mediastinal and hilar lymph node enlargement, pleural effusion, or pleural thickening). In case
113 of discordance between the interpretations of the two radiologists, the opinion of a third deputy
114 chief physician radiologist was sought to reach a final decision. Data on follow-up, prognosis,

115 and treatment were updated on April 24, 2020.

116 2.4. Statistical analyses

117 Continuous variables were expressed as medians with interquartile ranges (IQR), and
118 categorical variables were reported as frequencies and percentages. Differences between
119 groups were compared using the independent samples t-test or Mann-Whitney test. The single
120 factor analysis of variance (ANOVA) or Kruskal-Wallis H test was used, as appropriate, to
121 compare the difference among the four groups into which patients were divided based on
122 severity of the disease. Least significant difference (LSD) or Dunn's test was used for post hoc
123 comparisons. Categorical data were analyzed either with Pearson Chi-square test or with
124 Fisher's exact test. Two-tailed tests were performed to determine statistical significance at the
125 5% level. Bonferroni correction was used for pairwise comparison.

126 Univariable and multivariable analyses for factors associated with the time for nucleic acid test
127 to turn negative and the time of improvement of symptoms were performed with multiple
128 linear regression analyses. Univariable and multivariable analyses for factors that are
129 associated with chest CT improvement were done with Kaplan-Meier method and Cox
130 proportional hazards regression model. Univariable and multivariable analyses for risk factors
131 for disease severity and the relationship between age and disease severity were performed with
132 logistic regression analyses. All data analyses were carried out using IBM Statistical Package
133 for the Social Sciences for Windows, version 25 (SPSS Inc., Chicago, Illinois), and graphs
134 were created using GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, CA,
135 USA). P value less than 0.05 was considered statistically significant.

136 **3.Results**

137 The median age of the patients was 52.8 years (IQR, 19–82). Male patients accounted for
138 46.7% of all patients. Based on severity, 12 patients (7.1%) had mild COVID-19, 137(81.1%)
139 patients had moderate type, 13(7.7%) patients had severe type, and 7(4.1%) patients had
140 critical type. The median number of days from the onset of illness to admission was 11.6 days
141 (IQR, 18–92). Fifty-two patients had comorbidities, including hypertension, cardiovascular
142 disease, diabetes, malignancy, cerebrovascular disease, chronic obstructive pulmonary
143 disease(chronic obstructive pulmonary disease), chronic nephropathy, immunosuppression,
144 and others. The most common morbidity was hypertension(17.8%). Clinical symptoms
145 included fever, cough, sputum production, dry cough, pharyngalgia, shortness of breath,
146 hemoptysis, myalgia, digestive symptoms, hypodynamia, and others. Fever was the most
147 common symptom (76.9%), followed by dry cough (68%). Among the 169 patients, the
148 lymphocyte count was decreased in 111 (65.68%) patients (median=1.24 (IQR=0.18–4.11)
149 $\times 10^9/L$). C-reactive protein (CRP) increased in 102 (65.39%) patients, lactate dehydrogenase
150 (LDH) increased in 52 (33.33%) patients, and D-dimer increased in 55 (35.95%) patients.
151 Alanine transaminase or aspartate aminotransferase was elevated in 56 patients (33.17%).
152 Serum creatinine was elevated in 5 patients (2.96%), 4 patients had chronic nephropathy, and 1
153 patient's renal function returned to normal after treatment. One hundred and fifty-four (90.1%)
154 patients received antiviral therapy within the first 3 days. Antivirals used included lopinavir,
155 tonavir, abidor, ribavirin, ganciclovir, and oseltamivir. Most patients (53.9%) received
156 antibacterial therapy, including moxifloxacin, cephalosporins, and azithromycin. Forty-eight
157 (28.4%) patients received corticosteroids. One hundred and sixty-five (97.60%) patients
158 improved, while four patients died.

159 Among the 169 patients, 121 were from hospitals in Wuhan, while 48 were from hospitals
160 in Guangxi. We compared the clinical data between the two groups. The Guangxi group had
161 fewer days from onset of illness to admission (5.24:14.09) ($p<0.05$). Cough and sputum
162 production were more common in the Wuhan group($p<0.05$). The total protein and albumin in
163 patients from Wuhan group were lower, while LDH was higher ($p<0.05$). The four patients
164 who died were all in Wuhan group (Table 1).

165 Among the 4 age groups into which patients were stratified, groups C and D had higher
166 proportions of severe and critical disease than the other 2 groups, and group C had the highest
167 proportion of severe disease among the 4 groups. Group A had the least proportion of patients
168 with dyspnea, while group C had the highest. In both group C and group D, oxygen
169 saturation(SpO_2)was lower than 94%, and group C had the lowest SpO_2 .The lymphocyte
170 count was lower in groups C and D than in groups A and B. LDH in group A was the lowest.
171 CRP, pro-calcitonin (PCT), and interleukin (IL)-6 were significantly higher in groups C and D
172 than in groups A and B. (Table2).

173 Fifty-two patients (30.8%) in the study had comorbidities. Compared with patients who had no
174 comorbidities, the percentage of critical COVID-19 was higher in the comorbidities
175 group(11.6%vs.0.9%; $p<0.05$).Patients with comorbidities were also more likely to have
176 dyspnea(36.5% vs. 16.2%; $p<0.05$).The total protein and albumin values and lymphocyte
177 counts in patients with comorbidities were lower, while increase in CRP and LDH was more
178 obvious in this group.All4 patients who died had comorbidities(Table3).

179 To determine the association of disease severity with age, we divided all patients into 5 groups
180 at intervals of 15 years, and analyzed the frequencies of severe and critical disease. We found

181 that older patients had higher proportion of severe or critical disease(Table 4).The 169 patients
182 were also divided into two groups—mild group(including mild type and moderate type
183 COVID-19,n=148) and severe group(including severe and critical type COVID-19,
184 n=21)—and we then analyzed the risk factors for disease severity. The results showed that
185 lymphocyte count and SpO₂ at admission were factors that determined the risk factor of
186 disease severity (Table5).

187 A total of 116 patients with CT image data were enrolled in this study. The average time from
188 onset of illness to CT imaging was 10.73 ± 7.97 (0–34) days. The first CT imaging findings of
189 the 116 patients were analyzed, and we found that 84(72.41%) patients had bilateral lung
190 involvement,88(75.86%) patients hadperipheral lesions, and99(85.3%) patients had
191 involvement of two or more lung lobes. The most common CT features were consolidation
192 (66.4%), GGO (55.2%), linear opacity (55.20%), and mixed GGO and consolidation (33.60%).
193 Forty (34.48%) patients had vascular thickening.

194 We further divided the patients into 6 groups according to the number of days from onset
195 of illness to repeat chest CT imaging: group1(≤ 7 days, n=59), group2(8–14days, n=92),
196 group3(15–21days, n=109), group4(22–28days, n=60), group5(29–45days, n=52), and
197 group6(46–60days, n=18). Among the groups, group 1 had the highest percentage of GGO
198 (48cases,81.4%), and the least percentage of linear opacity (20cases, 33.9%). Group 2 had the
199 highest percentage of consolidation (72cases,78.3%). The proportion of cases with linear
200 opacity gradually increased from group1 to group6, reaching 98.1% in group6.There were
201 4casesof reticular changes in group1,and the proportion gradually increased to group 6, in
202 which there were 7cases(Table 6).

203 To monitor the changes in CT images during the course of the disease, we considered the
204 dynamic changes in the CT images of two patients from Guangxi, from onset to improvement
205 of the disease: one with severe disease (patient1, Figure1) and the other with moderate disease
206 (patient 2, Figure 2). As shown in Figure 1, patient 1 had ground glass opacity on chest CT in
207 the early stage of the disease, and consolidation was noted on chest CT done on day 13 from
208 onset of illness, as the patient's clinical symptoms improved. Consolidation had resolved on
209 day 18 from onset of illness. Finally, the patient had linear opacity on day 23 from onset of
210 illness. There were fifty-one patients when their clinical symptoms improved and they had
211 checked chest CT (no more than 1 day before and after). Among them, the first CT findings
212 were mainly GGO in 36 cases. When their clinical symptoms improved, 16 cases (44.4%)
213 showed resolution of ground glass opacities but increased consolidation on repeat CT imaging,
214 while 16 cases (44.4%) showed both GGO and resolution of consolidation.

215 All 169 patients had positive real-time RT-PCR for COVID-19 nucleic acid on nasopharyngeal
216 swab specimens. Twenty-five patients underwent nucleic acid test on stool samples: seven of
217 them were positive, and six among them had diarrhea. Twenty patients underwent nucleic acid
218 test of urine samples: one was positive, but he did not have symptoms of urinary tract infection.
219 Vaginal secretions and semen tests were performed in 6 patients, all of which were negative.

220 We designed three prognostic models: model 1 was based on number of days from positive
221 COVID-19 nucleic acid test to negative test, model 2 was based on number of days from onset
222 of illness to improvement in symptoms, and model 3 was based on whether the second CT scan
223 was better than the first. There were 79 cases included in model 1, and multivariable analysis
224 showed that lymphocyte count was significantly associated with the number of independent

225 risk factor of days for positive COVID-19 nucleic acid test to become negative (Table 7, Figure
226 3). There were 53 cases included in model 2, and multivariable analysis showed that number of
227 days from onset of illness to confirmation of diagnosis was significantly associated with an
228 independent risk factor of the time it took for symptoms to improve (Table 8, Figure 4). The
229 average number of days from the first CT scan to the second CT scan was 5.35 days, and we
230 took 6 days as the time point for evaluating whether the CT scans improved or not. A total of 62
231 patients were included in model 3, and multivariable analysis showed that number of days from
232 onset of illness to confirmation of diagnosis and disease severity were significantly associated
233 with independent risk factors of chest CT improvement (Table 9).

234 **4. Discussion**

235 This study summarizes the clinical characteristics, laboratory findings, dynamic changes in CT
236 images, treatment, and prognosis of 169 COVID-19 patients from 5 hospitals in a western
237 China city and in the city of disease onset, Wuhan. The study included mostly mild cases of
238 COVID-19, which accounted for 88.2%. We analyzed the disease progression in three ways:
239 number of days from positive COVID-19 nucleic acid test to negative test, number of days
240 from onset of illness to improvement in symptoms, and improvement in second CT scan
241 compared to the first. At present, no similar large sample data has been reported.

242 The study showed that the common symptoms of COVID-19 were fever, cough, sputum
243 production, dyspnea, diarrhea, and myalgia. The main abnormalities in laboratory tests
244 included that lymphocytopenia and increase in levels of CRP, LDH, and D-dimer, while PCT
245 was normal. These findings are consistent with other literature reports.^{4,5,8,9} The most
246 common comorbidities were hypertension, cardiovascular disease, and diabetes. Chronic

247 obstructive pulmonary disease was rare. Both clinical symptoms and laboratory tests indicated
248 that patients with comorbidities had worse course of the disease, with higher proportion of
249 severe or critical disease and poorer prognosis. Patients with comorbidities manifested with
250 more dyspnea, lower lymphocyte count, and higher LDH, compared with those who had no
251 comorbidities. These were manifestations of COVID-19 disease, rather than worsening
252 symptoms of the comorbidities due to infection with SARS-Cov-2. We also found that the
253 proportion of critical type COVID-19 increased with age. Lower lymphocyte count and
254 SpO₂ were found in a higher proportion of patients with severe or critical type. These findings
255 suggest that healthcare providers should pay particular attention to age, comorbidities,
256 lymphocyte count, and SpO₂ in the diagnosis and treatment of COVID-19. These factors may
257 predict the progression of the patient from moderate to severe or critical type.

258 Early CT findings showed that the lung lesions were mainly bilateral, mainly involved two
259 or more lobes, and were mainly distributed in the peripheral zones of the lung. GGO,
260 consolidation and mixed GGO and consolidation were the most common CT findings, while
261 pleural effusion was rare. This is also consistent with previous literature reports.¹⁰ Through
262 statistical analysis of lung CT imaging on different days in the course of the disease, we found
263 the following progression: the early CT finding was GGO (1–7 days); the GGO lesion resolved
264 or gradually evolved into consolidation shadow (1–2 weeks); consolidation resolved (2–3
265 weeks); then, linear opacity or reticular changes developed (4–6 weeks). The whole course took
266 about a month. In the statistical analysis of the correlation between symptom improvement and
267 pulmonary imaging changes in 36 patients, nearly half of the patients (16/36) showed
268 resolution of GGO lesions and aggravation of consolidation lesions when the clinical

269 symptoms improved. Histological Lung biopsy specimen showed interstitial mononuclear
270 inflammatory infiltrates (dominated by lymphocytes), diffuse alveolar damage with cellular
271 fibro-myxoid exudate, or hyaline membrane formation.¹¹ This is different from what is seen in
272 bacterial pneumonia. Therefore, the change in extent of GGO lesions can be used to predict the
273 outcome of the disease, while consolidation shadow should not be used as a prognostic factor
274 for the patients' condition.

275 In this study, all patients had positive nucleic acid tests for pharyngeal swabs. Seven cases had
276 positive nucleic acid test for stool samples, but only six cases had diarrhea. One patient tested
277 positive for urine nucleic acid test, which is a rare report at present, and may suggest that
278 SARS-Cov-2 may cause urinary tract infection.

279 Most of the patients in this study were treated with antiviral drugs, including lopinavir and
280 tonavir. Currently, there are no research data that show that such drugs have a clear effect on
281 COVID-19. In this study, we found that the lower the lymphocyte count, the more the number
282 of days for nucleic acid test to change from positive to negative. The longer the duration from
283 onset of illness to admission, the longer the duration before improvement of symptoms, and the
284 shorter the duration from onset of illness to admission, the shorter the duration for CT image
285 improvement. Comparing patients in Hubei and Guangxi, we found that patients from Hubei
286 had more severe disease and more days from onset of illness to admission than those from
287 Guangxi. All of these findings suggest that early isolation, early diagnosis, and early initiation
288 of management can contribute to slowing down the progression and spread of COVID-19.

289 The present study has some limitations. First, due to the limited number of cases, some
290 results need to be further validated with more patients. Second, the effect of antiviral agents

291 and corticosteroidson COVID-19 needs further validation. Prospective studies should be
292 performed to get more accurate results. Third, because this was a retrospective analysis, the
293 time of CT imaging and nucleic acid test was not standardized and unified, t may have reduced
294 the accuracy of the result. More cases need to be analyzed to obtain more information.

295 **5.Conclusions**

296 In this study, we found that older patients and patients with comorbiditieshad higher proportion
297 of severe or critical type COVID-19. Lymphocyte count and and SpO2 at admission were
298 associated with disease severity. Early isolation, early diagnosis, and early initiation of
299 management can contribute to slowing down the progression and spread ofCOVID-19. These
300 findings will be helpful for the diagnosis and treatment of COVID-19.

301 **Funding**

302 This research received no external funding.

303 **Disclosure**

304 The authors declare no conflicts of interest associated with this manuscript.

305

306 **Author Contributions**

307 WZ made substantial contributions to the conception and design of the study; acquisition, analysis, and
308 interpretation of the data; and drafting of the manuscript. XF, JH, CD and DQ made substantial contributions to
309 the conception and design of the study; acquisition, analysis, and interpretation of the data; and critical revision
310 of the manuscript for important intellectual content. XZ and JZ also gave final approval of the version to be
311 published and agree to be accountable for all aspects of the work in ensuring that questions related to the

312 accuracy and integrity of any part of the work are appropriately investigated and resolved. JZ gave final
313 approval of the version to be published. WZ and XF participated in analysis and interpretation of the data and
314 agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity
315 of any part of the work are appropriately investigated and resolved. WZ and JZ conceived of the study,
316 participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript.

317 **Acknowledgements**

318 We would like to thank the three radiologists, Drs. Yanyan Shen, Peng Peng, Dong Deng, who helped with the
319 analysis and interpretation of the imaging data.

320 **Ethical approval**

321 This study was approved by the ethics committee associated with the Faculty of Medicine at The First Affiliated
322 Hospital of Guangxi Medical University[2020(KY-E-06)]. Informed consent was done appropriately for
323 subjects.

324

325 **References**

- 326 1. World Health Organization. Situation Report-102. Available at:
327 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19-sitrep.pdf?sfvrsn=7](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19-sitrep.pdf?sfvrsn=742f4a18_4)
328 42f4a18_4. Accessed May 1, 2020.
- 329 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
330 China. *Lancet* 2020;395:496. doi: 10.1016/S0140-6736(20)30252-X.
- 331 3. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus
332 disease 2019 (COVID-19) pneumonia. *Am J Roentgenol* 2020;1-6. doi: 10.2214/AJR.20.22961.
- 333 4. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. *Am J*

- 334 Respir Crit Care Med 2020;201:1380-8.
- 335 5.Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
336 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.doi:
337 10.1016/S0140-6736(20)30211-7.
- 338 6.Rong W, Lingli X, Peng D, Fan H, Song M. Clinical characteristics of 96 hospitalized patients with
339 coronavirus disease 2019.Chin J Respir Crit Care Med 2020;19:144-7.
- 340 7. China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and
341 Treatment (7th edition). Available at: <http://kify.meetingchina.org/msite/news/show/cn/3337.html>. Accessed on
342 April 1, 2020.
- 343 8.Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for
344 fighting the storm. Eur J Clin Invest2020;50:e13209.doi: 10.1111/eci.13209.
- 345 9.Holshue ML, Debolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J
346 Med2020;382:929-36.doi: 10.1056/NEJMoa2001191.
- 347 10.Li B, Li X, Wang Y, et al. Diagnostic value and key features of computed tomography in coronavirus disease
348 2019.Emerg Microbes Infect2020; 9:787-93.doi: 10.1080/22221751.2020.1750307.
- 349 11.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress
350 syndrome. Lancet Respir Med2020;8:420-2.doi: 10.1016/S2213-2600(20)30076-X.
- 351
- 352
- 353
- 354
- 355

356

357

358

359

360

361

362

363 **Table1: Clinical features of study subjects in different locations**

Characteristics	All (n=169)	Locations		p value
		Wuhan(n=121)	Guangxi(n=48)	
Median age (IQR) - yrs	52.8 (18–92)	53.9 (25–92)	47.9 (18–85)	0.027
Sex - no./total no.(%)				0.881
Male	79/169 (46.7)	57/121 (47.1)	22/48 (45.8)	-
Female	90/169 (53.3)	64/121 (52.9)	26/48 (54.2)	-
Disease Severity- no./total no.(%)				0.073
Mild	12/169 (7.1)	5/121 (4.1)	7/48 (14.6)	-
Moderate	137/169(81.1)	103/121 (85.1)	34/48 (70.8)	-
Severe	13/169 (7.7)	8/121 (6.6)	5/48 (10.4)	-
Critical	7/169 (4.1)	5/121 (4.1)	2/48 (4.2)	-
Days from onset of illness to admission - median days (IQR)	11.66 (0–45)	14.09 (0–45)	5.24 (1–20)	<0.001
Symptoms - no./total no.(%)				
Fever	130/169(76.9)	96/121 (79.3)	34/48 (70.8)	0.237
Dry cough	115/169 (68)	88/121 (72.7)	27/48 (56.3)	0.038

Sputum production	46/169 (27.4)	45/121 (37.5)	1/48 (2.1)	<0.001
Shortness of breath	38/169 (22.5)	31/121 (25.6)	7/48 (14.6)	0.121
Myalgia	15/169 (8.9)	14/121 (11.6)	1/48 (2.1)	0.070
Digestive symptoms	29/169 (17.3)	22/121 (18.3)	7/48 (14.6)	0.576
Comorbidities- no./total no. (%)				
Any comorbidity	52/169 (30.8)	40/121 (33.1)	12/48 (25.0)	0.306
Hypertension	30/169 (17.8)	23/121 (19.0)	7/48 (14.6)	0.497
Cardiovascular disease	14/169 (8.3)	11/121 (9.1)	3/48 (6.3)	0.759
Diabetes	11/169 (6.5)	10/121 (8.3)	1/48 (2.1)	0.183
Malignancy	1/169 (0.6)	1/121 (0.8)	0/48 (0)	1.000
Cerebrovascular disease	5/169 (3.0)	5/121 (4.1)	0/48 (0)	0.323
COPD or chronic bronchitis	4/169 (2.4)	4/121 (3.3)	0/48 (0)	0.579
Others	10/169 (5.9)	9/121 (7.4)	1/48 (2.1)	0.285
Laboratory findings- median (IQR)				
SpO₂-%	95.73 (70–100)	95.72 (70–100)	96 (87–100)	0.364
Total protein - g/L	68.69 (36.7–98.0)	66.68 (36.7–98.0)	73.62 (54.7–86.3)	<0.001
Albumin - g/L	38.8(18–53.8)	37.78 (18–53.8)	41.19 (24.6–53.0)	0.004
Globulin - g/L	29.86 (9.8–54.5)	28.87 (9.8–47.2)	32.38 (23.0–54.5)	0.002
Total bilirubin - µmol/L	12.72 (2.7–62.0)	14.13 (5.8–49.2)	9.88 (2.7–62.0)	0.011
ALT-U/L	44.62	49.98 (2.0–547.7)	30.46 (18.0–65.2)	0.006

	(2.0–574.7)			
AST-U/L	42.83 (5.0–584.0)	47.79 (9.0–584)	29.74 (5.0–72.8)	0.007
GGT-U/L	78.24 (7–906)	74.69 (7–906)	130.3 (9–601)	0.585
Creatinine - $\mu\text{mol/L}$	73.4 (34.5–359)	75.88 (39–359)	68.2 (34.5–245)	0.276
White blood cell count - $\times 10^9/\text{L}$	7.07(1.01–65)	7.18 (1.01–65)	6.77 (2.3–19.4)	0.731
Neutrophilcount - $\times 10^9/\text{L}$	5.12 (0.52–55.6)	5.17 (0.52–55.6)	5 (0.8–17.6)	0.862
lymphocyte cell count - $\times 10^9/\text{L}$	1.24 (0.18–4.11)	1.26 (0.18–4.11)	1.18 (0.20–2.40)	0.454
Hemoglobin - g/L	130.51 (84–230)	130.39 (84–230)	131.13 (96–219)	0.873
Platelet count - $\times 10^9/\text{L}$	222.35 (55–564)	219.12 (55–538)	238.78 (119–564)	0.328
C-reactive protein - mg/L	33.77 (0.04–285)	31.19 (0.04–254.35)	40.05 (0.5–285)	0.316
PCT - $\mu\text{g/mL}$	0.35 (0.02–6.02)	0.37 (0.02–6.02)	0.29 (0.02–2.94)	0.468
LDH - U/L	263.16 (120–808)	281.56 (120–808)	227.65 (151–610)	0.009
Creatine kinase - U/L	107.53 (12–1381)	110.94 (28–1381)	101.81 (12–355)	0.745
CK-MB - U/L	13.91 (1–73)	13.02 (4–45.7)	15.12 (1–73)	0.305
PT-s	14.65 (9.7–100)	15.43 (9.7–100)	13.09 (10.5–17)	0.081
D-dimer - $\mu\text{g/ml}$	2.16 (0–89)	2.7 (0–89)	0.76 (0.02–20.58)	0.292
Treatment- no./total				

no. (%)				
Antiviral	91/169(53.85)	73 (60.30)	18 (37.50)	0.007
Antibiotics	154/169	108 (89.30)	46 (95.80)	0.291
	(91.10)			
Corticosteroids	48/169(28.40)	42 (34.70)	6 (12.50)	0.004
Outcome- no./total no.				0.561
(%)				
Improvement	165/169	117/121 (96.70)	48/48 (100)	
	(97.60)			
Death	4/169 (2.40)	4/121 (3.30)	0/48 (0)	

364 IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase,
 365 AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate
 366 dehydrogenase, CK-MB=creatinase-MB, PT=prothrombin time

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385 **Table2: Clinical features of study subjects according to age group**

	Age –yrs				p value
	Group A 18–44 (n=52)	Group B 45–64 (n=70)	Group C 65–74 (n=35)	Group D ≥75 (n=12)	
Sex - no./total no.(%)					0.743
Male	21/52 (40.4)	35/70 (50.0)	17/35 (48.6)	6/12 (50.0)	
Female	31/52 (59.6)	35/70 (50.0)	18/35 (51.4)	6/12 (50.0)	
Disease severity- no./total no.(%)					0.002
Mild	8/52 (15.4)	3/70 (4.2)	1/35 (2.9)	0/12 (0)	0.077
Moderate	41/52 (78.8)	63/70 (90)	24/35 (68.6)	9/12(75.0)	0.054
Severe	3/52 (5.8)	2/70 (2.9)	7/35 (20.0) ^{AC}	1/12(8.3)	0.015
Critical	0/52 (0)	2/70 (2.9)	3/35 (8.5)	2/12(16.7) ^{AD,BD}	0.020
No. of days from illness onset to admission – median(IQR)	8.2 (0–32)	14.4 (1–40) ^{AB}	12.3 (1–45) ^{AC}	9.5 (0–20)	0.009
Symptoms - no./total no.(%)					
Fever	34/52 (65.4)	60/70 (85.7)	27/35 (77.1)	9/12 (75.0)	0.073
Dry cough	33/52 (63.5)	46/70 (65.7)	26/35 (74.3)	10/12 (83.3)	0.459

Sputum production	10/52 (19.2)	22/70 (31.9)	11/35 (31.4)	3/12 (25)	0.43
Shortness of breath	3/52 (5.8)	14/70 (20.0) ^{AB}	17/35 (48.6) ^{AC}	4/12 (33.3) ^{AD}	<0.001
Myalgia	2/52 (3.8)	8/70 (22.4)	4/35 (11.4)	1/12 (8.3)	0.395
Digestive symptoms	9/52 (17.3)	11/70 (15.7)	7/35 (20)	2/12 (16.7)	0.944
Comorbidities - no./total no.(%)					
Any comorbidity	6/52 (11.5)	21/70 (30)	19/35 (54.3)	6/12 (50.0)	<0.001
Hypertension	3/52 (5.8)	10/70 (14.3)	12/35 (34.3)	5/12 (41.7)	0.001
Cardiovascular disease	2/52 (3.8)	7/70 (10.0)	5/35 (14.3)	0/12 (0)	0.257
Diabetes	0/52 (0)	2/70 (2.9)	8/35 (22.9)	1/12 (8.3)	<0.001
Malignancy	0/52 (0)	0/70 (0)	1/35 (2.9)	0/12 (0)	0.278
Cerebrovascular disease	0/52 (0)	0/70 (0)	1/35 (2.9)	4/12 (33.3)	<0.001
COPD	0/52 (0)	0/70 (0)	3/35 (8.5)	1/12 (8.3)	0.006
Others	2/52 (3.8)	5/70 (7.1)	2/35 (5.7)	1/12 (8.3)	0.825
Laboratory findings- median (IQR)					

SpO ₂ -%	97.31 (93–100)	96.17 (70–99)	93.26 (76–98)	93.55 (80–98)	0.032
Total protein - g/L	73 (57–86.3)	68.5 (36.7–98) ^{AB}	63.5 (53.4–82.2) ^{AC,BC}	65.7 (51–81.8) ^{AD}	<0.001
Albumin - g/L	43.3 (32.6–53)	38.6 (18–53.8)	33.3 (20–44.5)	36.1 (27–44)	<0.001
Globulin - g/L	29.7 (22–39.7)	29.9 (9.8–47.2)	30 (19–54.5)	29.5 (18–41.8)	0.947
Total bilirubin - μmol/L	11.9 (2.91–49.2)	11.5 (2.8–33)	12.8 (2.7–48)	20.5 (5.9–62)	0.151
ALT-U/L	45 (7–547.7)	50.4 (11–479)	32.3 (10–81)	41.5 (2–101)	0.626
AST-U/L	35.1 (9–352.7)	49.2 (13–584)	38.1 (5–157)	51.6 (20–109.2)	0.540
GGT-U/L	93.5 (10–906)	82.2 (8–527)	72.8 (7–601)	44 (7–906)	0.766
Creatinine - μmol/L	61 (34.5–91)	74.2 (41–241)	78 (46.1–245)	104.5 (60–359)	0.001
White blood cell count - ×10 ⁹ /L	6.78 (2.3–60.9)	7.46 (2.34–65)	7.1 (1.01–19.4)	5.9 (1.92–13.61)	0.893
Neutrophil count - ×10 ⁹ /L	4.76 (0.8–55.6)	5.2 (1.12–20.71)	5.62 (0.52–17.6)	5.1 (1.03–10.66)	0.91
Lymphocyte count - ×10 ⁹ /L	1.43(0.43–3.3)	1.31(0.23–4.11)	0.94(0.18–2.2) ^{AC,BC}	0.85(0.2–2.07) ^{AD,BD}	0.001
Hemoglobin - g/L	137.47 (102–230)	131.48 (100–191)	123.5 (84–177)	114.72 (87–147)	0.001
Platelet count - ×10 ⁹ /L	218.5 (55–431)	225.73 (84–564)	243 (100–538)	167.36 (85–250)	0.108

C-reactive protein - mg/L	17.76 (0.04–78.95)	30.11 (0.4–149.68)	46.84 (0.4–285)	88.57 (1–254.35)	0.006
PCT -µg/mL	0.21 (0.02–0.67)	0.34 (0.04–2.57)	0.49 (0.03–6.02)	0.56 (0.08–2.05)	0.017
LDH - U/L	212.86 (120–681)	275.74 (123–686) ^{AB}	282.2 (175–544) ^{AC}	369.09 (177–808) ^{AD}	<0.001
Creatinekinase - U/L	117.42 (31.4–1381)	101.87 (28–355)	88.87 (12–216)	120.6 (43–600)	0.891
CK-MB - U/L	14.09 (5–68)	12.75 (4–45.7)	17.34 (6–73)	16.52 (5–32.26)	0.405
PT-s	0.24 (0.01–1.23)	0.88 (0–7.8)	4.23 (0.02–80)	10.66 (0.18–89) ^{AD,BD,CD}	<0.001
D-dimer - µg/ml	13.16 (9.7–15.8)	13.37 (9.7–29.3)	15.57 (10.9–76)	21.87 (12.6–100) ^{AD,BD}	0.001
Immunology – median (IQR)					
IgG- g/L	11.53 (7.84–15.16)	13.39 (7.42–20.81)	12.66 (7.96–16.69)	12.75 (7.24–19.18)	0.647
IgA- g/L	2.15 (1.32–3.44)	2.63 (1.37–5.09)	2.07 (1.47–3.34)	2.65 (2.38–4.71)	0.26
IgM- g/L	1.42 (0.64–2.29)	1.53 (0.64–3.15)	1.37 (0.82–2.55)	1.18 (0.38–2.49)	0.662
IgE- g/L	74.77 (2.4–480.1)	124.38 (1.3–1100)	32.85 (0.8–76.1)	154.15 (2.8–1008)	0.717
IL-6- pg/mL	1.69 (15–2.84)	6.76 (1.5–42.53)	33.57 (1.5–223.81)	71.34 (2.89–252.7)	0.007
C3- g/L	0.94 (0.8–1.3)	0.94 (0.6–1.3)	0.85 (0.8–1)	0.94 (0.6–1.4)	0.701

C4- g/L	0.199 (0.1–0.4)	0.18 (0.1–0.3)	0.18 (0.1–0.2)	0.22 (0.1–0.4)	0.61
CD3+ cell count - cell/ μ l	1057.83 (243–1736)	785.66(377–1357)	577.28(142–1310)	–	0.015
CD4+ cell count - cell/ μ l	666.77(79–1320)	520.5(207–1000)	402.57(79–883)	–	0.081
CD8+ cell count - cell/ μ l	391.05(107–892)	265.16(75–548)	174.71(58–427)	–	0.011
CD4+ cell percentage - %	–	45.87 (42.32–50.93)	39.85 (10.83–59.3)	31.23	0.546
CD8+ cell percentage - %	–	24.77 (22.08–28.67)	26.18 (14.67–46.04)	15.54	0.436
CD3+ cell percentage - %	–	72.84 (70.68–74.79)	68.87 (58.64–86.66)	47.77	0.195
NK cell percentage - %	–	5.18 (3.54–6.47)	11.71 (2.69–27.59)	7.64	0.346
Number of lung lobes involved - no./total no.(%)					
5	12/45 (26.7)	29/48 (60.4)	16/25 (64.0)	5/10 (50.0)	0.003
4	2/45 (4.5)	7/48 (14.6)	2/25 (8.0)	0/10 (0)	0.336
3	3/45 (6.7)	4/48 (8.3)	4/25 (16.0)	4/10 (4.0)	0.032
2	11/45 (24.4)	4/48 (8.3)	2/25 (8.0)	0/10 (0)	0.073
1	11/45 (24.4)	2/48 (4.2)	0/25 (0)	1/10 (10.0)	0.003

0	6/45 (13.3)	2/48 (4.2)	1/25 (4.0)	0/10 (0)	0.343
Treatment - no./total no.(%)					
Antiviral	21/52 (40.4)	39/70 (55.7)	25/35 (71.4)	6/12 (50.0)	0.047
Antibiotics	48/52 (92.3)	66/70 (94.3)	32/35 (91.4)	8/12 (66.7)	0.001
Corticosteroids	6/52 (11.5)	19/70 (27.1)	18/35 (51.4)	0/12 (0)	0.001
Prognosis - no./total no.(%)					0.24
Death	0/52 (0)	2/70 (2.9)	1/35 (2.9)	1/12 (8.3)	
improve	52/52 (100.0)	68/70 (97.1)	34/35 (97.1)	11/12 (91.7)	

386 IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl
 387 transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatin kinase-MB, PT=prothrombin time, Ig=immunoglobulin, IL=interleukin,
 388 C3=complement 3, C4=complement 4, CD=cluster of differentiation, NK= natural killer
 389 Comparison between groups (P<0.05):AB= A compared with B, AC= A compared with C, AD=A compared with D, BC=B compared with C, BD=B compared with
 390 D, CD=C compared with D.
 391
 392
 393
 394
 395

396 **Table 3. Features of study subjects based on presence of comorbidities**

	Have comorbidities (N=52)	Have no comorbidities (N=117)	p value
Disease severity- no./total no.(%)			0.004
Mild	1/52 (1.9)	11/117 (9.4)	0.108
Moderate	40/52 (76.9)	97/117 (82.9)	0.360
Severe	5/52 (9.6)	8/117 (6.8)	0.542
Critical	6/52 (11.6)	1/117 (0.9)	0.004
Sex - no./total no.(%)			0.368
Male	27/52 (51.9)	52/117 (44.4)	-
Female	25/52 (48.1)	65/117 (55.6)	-
Age in yrs- median (IQR)	59.88 (25–86)	48.69 (18–92)	0.001
Days from onset of illness to confirmation of diagnosis - median (IQR)	11.18 (0–40)	11.86 (0–45)	0.691
Symptoms - no./total no.(%)			
Fever	43/52 (82.7)	87/117 (74.4)	0.235
Dry cough	39/52 (75.0)	76/117 (68.0)	0.196
Sputum production	17/52 (33.3)	29/117 (24.8)	0.253
Shortness of breath	19/52 (36.5)	19/117 (16.2)	0.004
Digestive symptoms	6/52 (11.5)	9/117 (7.7)	0.604
Myalgia	9/52 (17.6)	20/117 (17.1)	0.931
Laboratory findings-median (IQR)			
SpO₂- %	94.4 (70–99)	96.3 (72–100)	0.121

Total protein - g/L	65.66 (39–84)	70.06 (36.7–98)	0.004
Albumin - g/L	36.34 (18–53)	39.9 (20–53.8)	0.002
Globulin - g/L	29.28 (18–47.2)	30.12 (9.8–54.5)	0.458
Total bilirubin - µmol/L	16.65 (4.3–62)	10.91 (2.7–49.2)	0.006
ALT-U/L	33.96 (2–120)	49.32 (10–574.7)	0.046
AST-U/L	38.94 (5–207)	44.54 (9–584)	0.476
GGT-U/L	71.33 (10–601)	81.99 (7–906)	0.706
Creatinine - µmol/L	81.69 (43–359)	69.45 (34.5–241)	0.177
White blood cell count - ×10⁹/L	7.74 (1.01–65)	6.77 (1.92–60.9)	0.404
Neutrophil count - ×10⁹/L	5.44 (0.52–20.71)	4.96 (0.8–55.6)	0.646
Lymphocyte count - ×10⁹/L	1.07 (0.18–2.66)	1.31 (0.26–4.11)	0.032
Hemoglobin - g/L	127.95 (84–191)	131.57 (100–230)	0.331
Platelet count - ×10⁹/L	213.34 (85–392)	226.73 (55–564)	0.292
C-reactive protein - mg/L	49.72 (0.3–254.35)	27.22 (0.04–285)	0.026
PCT -µg/mL	0.53 (0.02–6.02)	0.27 (0.02–1.74)	0.091
ESR - mm/h	44.67 (20–97.3)	37.62 (9–119)	0.175
LDH - U/L	327.21 (123–808)	235.51 (120–681)	0.002
Creatinekinase - U/L	106.45 (12–600)	107.91 (28–1381)	0.961
CK-MB - U/L	16.37 (5–73)	12.68 (1–45.7)	0.181
D-dimer -µg/ml	3.33 (0–80)	0.71 (0.01–8.00)	0.175
PT-s	18.18 (10.9–100)	13.22 (9.7–17.4)	0.101
Immunological findings- median (IQR)			

IgG- g/L	2.32 (1.37–3.54)	2.46 (1.32–5.09)	0.625
IgA- g/L	1.43 (0.46–2.98)	1.37 (0.38–3.15)	0.785
IgM- g/L	120.19 (0.8–1100)	99.05 (1.3–1008)	0.770
IgE- g/L	11.5 (7.24–16.88)	13.03 (7.42–20.81)	0.229
C3- g/L	0.91 (0.6–1.2)	0.93 (0.6–1.4)	0.719
C4- g/L	0.18 (0.1–0.3)	0.2 (0.1–0.4)	0.433
IL-6- pg/mL	17.67 (1.5–124.8)	23.42 (0–252.7)	0.773
CD3+ cell count - cell/μl	65.6 (58.64–75.45)	69.59 (47.77–86.66)	0.487
CD4+ cell count - cell/μl	12.48 (2.69–27.59)	8.9 (3.54–18.76)	0.379
CD8+ cell counts - cell/μl	14.99 (1.8–37.85)	17.61 (3.3–37.33)	0.673
CD4+ cell percentage - %	36.61 (10.83–59.3)	42.41 (31.23–55)	0.376
CD8+ cell percentage - %	26.85 (14.67–46.04)	28.8 (15.54–73.05)	0.816
Days before negative nucleic acid test-median (IQR)	8.18 (2–30)	6.16 (1–18)	0.092
Treatment - no./total no. (%)			
Antibiotics	33/52 (63.50)	58/117 (49.6)	0.095
Antiviral	49/52 (94.2)	105/117 (89.7)	0.558
Corticosteroids	16/52 (30.8)	32/117 (27.4)	0.649
Outcome - no./total no. (%)			0.008
Death	4/52 (7.7)	0/117 (0)	
Improvement	48/52 (92.3)	117/117 (100)	

397 IQR=interquartile range, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma
398 glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatin kinase-MB,
399 ESR=erythrocyte sedimentation rate, PT=prothrombin time, Ig=immunoglobulin

400

401

402 Table 4:Relationship between age and disease severity (N=169)

Variable	B	Wald χ^2	P	95%CI
Q1	-4.604	32.983	0.000	(-6.175~-3.033)
Q2	0.512	0.586	0.444	(-0.799~1.823)
Q3	1.770	6.063	0.014	(0.361~3.180)
Age group (control: group 5)				
1	-2.675	8.098	0.004	(-4.518~-0.883)
2	-2.382	8.146	0.004	(-4.017~-0.746)
3	-1.768	5.022	0.025	(-3.314~-0.222)
4	-0.628	0.691	0.406	(-2.110~0.853)

403 Q1=Mild disease, Q2=Moderate disease, Q3=Severe disease, Q4=Critical disease

404 Age group (years, 15-year intervals): 1=18–32, 2=33–47, 3=48–62, 4=63–77, 5=78–92; B=regression

405 coefficient; OR=odds ratio; 95%CI=95% confidence interval

406

407 Table 5:Univariable and multivariable analyses of risk factors for disease severity (N=169)

Variable	Univariable analysis		Multivariable analysis		
	P	P	OR	95%CI	
SpO ₂ (%)	0.000	0.000	0.693	(0.572–0.839)	
Age(Year)	0.003	0.482	-	-	
Lymphocytes($\times 10^9/L$)	0.000	0.047	0.176	(0.032–0.976)	
CRP rise(No)	0.003	0.212	-	-	
LDH rise(No)	0.002	0.974	-	-	
Administration of corticosteroids	0.000	0.505	-	-	
Days from onset of illness to confirmation of	0.049	0.070	-	-	

diagnosis time				
Underlying disease(No)	0.043	0.185	-	
Albumin (g/L)	0.002	-	-	-
D-dimer ($\mu\text{g/ml}$)	0.019	0.307	1.056	(0.951–1.171)
Dyspnea(No)	0.000	0.270	-	-
Cough(No)	0.032	-	-	-

408 LDH=lactate dehydrogenase; CRP=C-reactive protein; OR=odds ratio; 95%CI=95% confidence interval

409

410

411

412

413

414

415

416

417

418

419

Table6: Chest CT findings of study subjects on different days*

	On admission	Group1(≤7 days)	Group2(8–14 days)	Group3(15–21days)	Group4(22–28days)	Group5(29–45 days)	Group6(46–60days)	p value
Number of patients	116	59	92	109	60	52	18	
Days from onset of illness to chest CT-median (IQR)	10.73±7.97 (0-34)	4.610±2.14 (0-7)	11.09±1.93 (8-14)	17.72±2.01 (15-21)	24.98±1.92 (22-28)	34.58±5.18 (29-45)	51.72±3.64 (45-57)	
Bilateral lung involvement - no./total no.(%)	84/116 (72.4)	39/59 (66.1)	68/92 (73.9)	87/109 (79.8)	51/60 (85)	39/52 (75)	12/18 (66.7)	0.158
Distribution of lesions in lung-no./total no.(%)								
Peripheral	88/116(75.86)	41/59 (69.49)	72/92 (78.26)	92/109 (84.40)	55/60 (91.67)	47/52 (90.38)	17/18 (94.44)	0.006
Along the bronchi	30/116(25.86)	10/59 (16.95)	32/92 (34.78)	33/109 (30.28)	12/60 (20.00)	11/52 (21.15)	2/18 (11.11)	0.049
Random	3/116 (2.59)	4/59 (6.78)	2/92 (2.17)	1/109 (0.92)	0/60 (0)	0/52 (0)	0/18 (0)	0.101
Diffuse	11/116 (9.48)	4/59 (6.78)	6/92 (6.52)	9/109 (8.26)	2/60 (3.33)	1/52 (1.92)	1/18 (5.56)	0.638
CT								

findings-no./total no.(%)								
Ground-glass opacity	64/116(55.2)	48/59(81.4)	48/92(52.2)	41/109(37.6)	17/60(28.3)	19/52(36.5)	8/18(44.4)	0.001#
Consolidation	77/116(66.4)	30/59(50.9)	72/92(78.3)	80/109(73.4)	37/60(61.7)	33/55(63.6)	14/18(77.8)	0.004@
Ground-glass opacity with consolidation	39/116(33.6)	16/59(27.1)	31/92(33.7)	34/109(31.2)	12/60(20.0)	16/55(29.1)	6/18(33.3)	0.337
Linear opacity	64/116(55.2)	20/59(33.9)	53/92(57.6)	91/109(83.5)	56/60(93.3)	51/52(98.1)	18/18(100)	0.001
Reticular change	15/116(12.93)	4/59(6.78)	5/92 (5.43)	18/109 (16.51)	13/60 (21.67)	13/52 (25.00)	7/18 (38.89)	0.001 ¥
Pleural thickening	6/116 (5.17)	0/59 (0)	3/92 (3.26)	9/109 (8.26)	7/60 (11.67)	9/52 (17.31)	3/18 (16.67)	0.001
Pleural effusion	2/116 (1.72)	1/59 (1.69)	0/92 (0)	2/109 (1.83)	1/60 (1.67)	1/52 (1.92)	0/18 (0)	0.753
Vascular thickening	40/116(34.48)	12/59 (20.34)	28/92 (30.43)	47/109 (43.12)	25/60 (41.67)	32/52 (61.54)	6/18 (33.33)	0.001
Number of lung lobes involved-no./total no.(%)								
5	56/116(48.28)	20/59 (33.90)	43/92 (46.74)	58/109 (53.21)	33/60 (55.00)	28/52 (53.85)	12/18 (66.67)	0.079

		6/59	7/92	14/109		7/52		
4	10/116(8.662)	(10.17)	(7.61)	(12.84)	6/60 (10.00)	(13.46)	0/18 (0)	0.530
		10/59	11/92	9/109	4/60	11/52	6/18	
3	16/116(13.79)	(16.95)	(11.96)	(8.26)	(6.67)	(21.15)	(33.33)	0.011
		12/59	20/92	18/109		4/52		
2	17/116(14.66)	(20.34)	(21.74)	(16.51)	12/60 (20.00)	(7.69)	0/18 (0)	0.100
		11/59	11/92	10/109	5/60	2/52		
1	17/116(14.66)	(18.64)	(11.96)	(9.17)	(8.33)	(3.85)	0/18 (0)	0.083

* Days from onset of illness to chest CT examination

CT=computed tomography, IQR=interquartile range

#: Group1 compared to other groups; Group2 compared to Group3 and Group4; p<0.05

@: Group1 compared toGroup2, Group3, and Group4; Group2 compared toGroup5; p<0.05

¥ : Group1 compared to other groups; Group2 compared to other groups; p<0.05

Table 7: Univariable and multivariable analysis of factors associated with the time it takes for nucleic acid test to turn negative (N=79)

Variable	Univariable analysis	Multivariable analysis		
	P	P	B	95%CI
Sex(Male)	0.079	-	-	-
Age(Year)	0.278	-	-	-
Lymphocytes($\times 10^9/L$)	0.005	0.014	-2.974	(-5.327~-0.620)
CRP(mg/L)	0.021	0.954	0.001	(-0.022~-0.024)
LDH(U/L)	0.005	0.730	0.003	(-0.012~-0.017)
Corticosteroids	0.005	0.137	-1.710	(-3.978~-0.557)
Antibiotics	0.024	0.154	-1.563	(-3.723~-0.598)

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 8: Univariable and multivariable analysis of factors associated with the time it takes for symptoms to improve (N=53)

Variable	Univariable analysis	Multivariable analysis		
	P	P	B	95%CI
Sex(Male)	0.724	-	-	-
Age(Year)	0.052	0.095	0.146	(-0.025~-0.319)
Lymphocytes($\times 10^9/L$)	0.029	0.440	1.713	(-2.708~-6.134)
CRP(mg/L)	0.993	-	-	-
LDH(μ/L)	0.792	-	-	-
Administration of corticosteroid	0.323	-	-	-
Time from onset of illness to confirmation of diagnosis (days)	0.000	0.001	0.527	(0.219~0.835)

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 9: Univariable and multivariable analysis of factors associated with chest CT improvement(N=62)

Variable	Univariable analysis	Multivariable analysis		
	P	P	HR	95%CI
Sex(Male)	0.023	0.109	0.608	(0.331–1.117)
Age(Year)	0.195	-	-	-
Lymphocytes($\times 10^9/L$)	0.088	0.278	1.374	(0.774–2.440)
CRP(mg/L)	0.561	-	-	-
LDH(U/L)	0.899	-	-	-
Administration of corticosteroid	0.540	-	-	-
Time from onset of illness to confirmation of diagnosis (days)	0.075	0.013	1.019	(1.019–1.168)
Disease severity	0.045	0.061	-	-
Moderate(compared to mild mild)	-	0.008	0.261	(0.097–0.704)
Severe(compared to mild mild)	-	0.057	0.192	(0.035–1.049)
Critical(compared to mild mild)	-	0.971	0	0
Time of onset to nucleic acid positive time(days)	0.059	0.853	1.009	(0.918–1.110)

CT=computed tomography, LDH=lactate dehydrogenase, CRP=C-reactive protein, HR=hazard ratio, 95%CI=95% confidence interval

Figure legends

Figure 1 : Computed tomography findings in the lungs on different days in the course of the disease in a patient with severe disease.(a)4 days from onset of illness.(b)8 days from illness onset (patient’s clinical symptoms began to improve) .(c)13 days from onset of illness. (d)18 days from onset of illness. (e)23 days from onset of illness onset.

Figure 2: Computed tomography findings in the lungs on different days in the course

of the disease in a patient with moderate disease. (a)5 days from onset of illness. (b)10 days from onset of illness (patient's clinical symptoms began to improve). (c)15 days from onset of illness. (d)21 days from onset of illness.

Figure 3: Correlations between: The days of nucleic acid test turned negative and lymphocytes;

Figure 4: Correlations between: Time from onset of symptoms to confirmation of diagnosis and Time it took for symptoms to improve.







